Free Trial
NASDAQ:RVPH

Reviva Pharmaceuticals (RVPH) Stock Price, News & Analysis

Reviva Pharmaceuticals logo
$0.54 +0.02 (+3.56%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$0.54 0.00 (-0.65%)
As of 08/22/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Reviva Pharmaceuticals Stock (NASDAQ:RVPH)

Key Stats

Today's Range
$0.52
$0.56
50-Day Range
$0.34
$0.80
52-Week Range
$0.30
$4.28
Volume
2.69 million shs
Average Volume
2.74 million shs
Market Capitalization
$36.62 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.17
Consensus Rating
Buy

Company Overview

Reviva Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
54th Percentile Overall Score

RVPH MarketRank™: 

Reviva Pharmaceuticals scored higher than 54% of companies evaluated by MarketBeat, and ranked 491st out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Reviva Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Reviva Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.

  • Read more about Reviva Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Reviva Pharmaceuticals are expected to grow in the coming year, from ($0.97) to ($0.79) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Reviva Pharmaceuticals is -0.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Reviva Pharmaceuticals is -0.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Percentage of Shares Shorted

    34.18% of the float of Reviva Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Reviva Pharmaceuticals has a short interest ratio ("days to cover") of 5.8.
  • Change versus previous month

    Short interest in Reviva Pharmaceuticals has recently increased by 97.52%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Reviva Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Reviva Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    34.18% of the float of Reviva Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Reviva Pharmaceuticals has a short interest ratio ("days to cover") of 5.8.
  • Change versus previous month

    Short interest in Reviva Pharmaceuticals has recently increased by 97.52%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Reviva Pharmaceuticals has a news sentiment score of 0.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 17 news articles for Reviva Pharmaceuticals this week, compared to 1 article on an average week.
  • Search Interest

    Only 21 people have searched for RVPH on MarketBeat in the last 30 days. This is a decrease of -32% compared to the previous 30 days.
  • MarketBeat Follows

    13 people have added Reviva Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 86% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Reviva Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    27.18% of the stock of Reviva Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    63.18% of the stock of Reviva Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Reviva Pharmaceuticals' insider trading history.
Receive RVPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Reviva Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RVPH Stock News Headlines

What is Zacks Small Cap's Estimate for RVPH FY2025 Earnings?
Roth Capital Issues Negative Outlook for RVPH Earnings
BREAKING: The House just passed 3 pro-crypto bills!
THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. tc pixel
RVPH: There May Be A Faster Way
See More Headlines

RVPH Stock Analysis - Frequently Asked Questions

Reviva Pharmaceuticals' stock was trading at $1.81 at the beginning of the year. Since then, RVPH shares have decreased by 70.2% and is now trading at $0.5385.

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) released its quarterly earnings results on Thursday, August, 14th. The company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.03.

Reviva Pharmaceuticals' top institutional shareholders include Armistice Capital LLC (5.61%), 683 Capital Management LLC (2.08%), Persistent Asset Partners Ltd (1.34%) and Geode Capital Management LLC (0.93%). Insiders that own company stock include Prabhu Narayan and Purav Patel.
View institutional ownership trends
.

Shares of RVPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Reviva Pharmaceuticals investors own include Sangamo Therapeutics (SGMO), Salesforce (CRM), Adobe (ADBE), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Airbnb (ABNB) and Marvell Technology (MRVL).

Company Calendar

Last Earnings
8/14/2025
Today
8/23/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:RVPH
CIK
1742927
Fax
N/A
Employees
5
Year Founded
N/A

Price Target and Rating

High Price Target
$17.00
Low Price Target
$2.00
Potential Upside/Downside
+1,230.9%
Consensus Rating
Buy
Rating Score (0-4)
3.13
Research Coverage
8 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.65)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$29.92 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
-259.17%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.90
Quick Ratio
0.54

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.01) per share
Price / Book
-53.85

Miscellaneous

Outstanding Shares
68,004,000
Free Float
34,957,000
Market Cap
$36.62 million
Optionable
Optionable
Beta
-0.05

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:RVPH) was last updated on 8/23/2025 by MarketBeat.com Staff
From Our Partners